CA2151742A1 - Compositions for Oral Delivery of Active Agents - Google Patents

Compositions for Oral Delivery of Active Agents

Info

Publication number
CA2151742A1
CA2151742A1 CA2151742A CA2151742A CA2151742A1 CA 2151742 A1 CA2151742 A1 CA 2151742A1 CA 2151742 A CA2151742 A CA 2151742A CA 2151742 A CA2151742 A CA 2151742A CA 2151742 A1 CA2151742 A1 CA 2151742A1
Authority
CA
Canada
Prior art keywords
compositions
carrier
active agent
active agents
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2151742A
Other languages
French (fr)
Other versions
CA2151742C (en
Inventor
Alfred A. Amkraut
Heechung Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alfred A. Amkraut
Heechung Yang
Alza Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfred A. Amkraut, Heechung Yang, Alza Corporation filed Critical Alfred A. Amkraut
Publication of CA2151742A1 publication Critical patent/CA2151742A1/en
Application granted granted Critical
Publication of CA2151742C publication Critical patent/CA2151742C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Abstract

Compositions and methods for the oral administration of drugs and other active agents are provided. The compositions comprise an active agent carrier particle attached to a binding moiety which binds specifically to a target molecule present on the surface of a mammalian enterocyte. The binding moiety binds to the target molecule with a binding affinity or avidity sufficient to initiate endocytosis or phagocytosis of particulate active agent carrier so that the carrier will be absorbed by the enterocyte. The active agent will then be released from the carrier to the host's systemic circulation. In this way, degradation of degradation-sensitive drugs, such as polypeptides, in the intestines can be avoided while absorption of proteins and polypeptides from the intestinal tract is increased.
CA002151742A 1993-02-22 1994-02-22 Compositions for oral delivery of active agents Expired - Fee Related CA2151742C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2048193A 1993-02-22 1993-02-22
US08/020,481 1993-02-22
PCT/US1994/001756 WO1994018955A1 (en) 1993-02-22 1994-02-22 Compositions for oral delivery of active agents

Publications (2)

Publication Number Publication Date
CA2151742A1 true CA2151742A1 (en) 1994-09-01
CA2151742C CA2151742C (en) 1999-05-25

Family

ID=21798853

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002151742A Expired - Fee Related CA2151742C (en) 1993-02-22 1994-02-22 Compositions for oral delivery of active agents

Country Status (9)

Country Link
US (2) US5620708A (en)
EP (1) EP0684814B1 (en)
JP (1) JPH08507070A (en)
AT (1) ATE167396T1 (en)
AU (1) AU6268894A (en)
CA (1) CA2151742C (en)
DE (1) DE69411154T2 (en)
MX (1) MX9401351A (en)
WO (1) WO1994018955A1 (en)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013250A1 (en) * 1994-10-27 1996-05-09 Amgem Inc. Compositions for increased bioavailability of orally delivered therapeutic agents
EP0805678B1 (en) * 1995-01-05 2003-10-29 THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN Surface-modified nanoparticles and method of making and using same
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
SI9720025A (en) * 1996-03-29 1999-08-31 Emishphere Technologies, Inc. Compounds and compositions for delivering active agents
CA2252438C (en) * 1996-04-19 2011-03-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
US6143037A (en) * 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
US6361938B1 (en) * 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
JP4203159B2 (en) * 1997-12-09 2008-12-24 株式会社林原生物化学研究所 Nerve function regulator
US6355270B1 (en) * 1999-01-11 2002-03-12 The Regents Of The University Of California Particles for oral delivery of peptides and proteins
AU5721900A (en) * 1999-03-08 2000-09-28 Lockheed Martin Corporation Single-pass interferometric synthetic aperture radar
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US8383081B2 (en) * 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en) * 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
EP1229924A4 (en) 1999-11-19 2004-12-15 Univ Leland Stanford Junior Targeted bifunctional molecules and therapies based thereon
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6537968B1 (en) * 2000-07-24 2003-03-25 Alphamed Pharmaceuticals Corp Treatment of lupus erythematosus
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
AU2002344371B2 (en) * 2001-06-01 2006-06-29 Novartis Ag Orally administering parathyroid hormone and calcitonin
AU2002364927A1 (en) * 2001-07-10 2003-06-30 North Carolina State University Nanoparticle delivery vehicle
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
CA2487720A1 (en) * 2002-06-03 2003-12-11 Alnis Biosciences, Inc. Therapeutic agent-containing polymeric nanoarticles
US20050129769A1 (en) * 2002-06-03 2005-06-16 Barry Stephen E. Polymeric articles for carrying therapeutic agents
SI1530482T1 (en) 2002-07-18 2014-03-31 Helix Biopharma Corp. Use of urease for inhibiting cancer cell growth
DE60336406D1 (en) 2002-10-16 2011-04-28 Purdue Pharma Lp ANTIBODIES BINDING TO CELL ASSOCIATED CA 125 / 0722P, AND METHOD FOR THEIR USE
NZ563471A (en) 2002-11-08 2009-04-30 Ablynx Nv Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders
BRPI0316092B8 (en) 2002-11-08 2021-05-25 Ablynx Nv single domain antibodies directed against tumor necrosis factor alpha and uses for them
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
US20040133099A1 (en) * 2002-12-18 2004-07-08 Dyer R. Kent Otologic nanotechnology
US20040157330A1 (en) * 2003-01-09 2004-08-12 Arizeke Pharmaceuticals, Inc. Compositions and methods for targeted biological delivery of molecular carriers
AU2004204262B2 (en) 2003-01-10 2010-11-04 Ablynx N.V. Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen
JP4684991B2 (en) * 2003-01-31 2011-05-18 ボストン サイエンティフィック リミテッド Local drug delivery using drug-loaded nanocapsules
DK1687338T3 (en) 2003-11-07 2011-02-07 Ablynx Nv Camelidae single-domain antibodies VHH targeting epidermal growth factor receptor and uses thereof
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
ATE480778T1 (en) 2004-04-15 2010-09-15 Athera Biotechnologies Ab METHOD FOR DETERMINING THE HAZARDS OF ISCHEMIC CARDIOVASCULAR DISEASE USING PHOSPHORYLCHOLINE CONJUGATES
CN101001641A (en) * 2004-04-29 2007-07-18 葛兰素伊斯特拉齐瓦基森塔萨格勒布公司 Oral formulations comprising bone morphogenetic proteins for treating metabolic bone diseases
US7906140B2 (en) * 2004-06-17 2011-03-15 Virun, Inc. Compositions for mucosal delivery of agents
US20060047025A1 (en) * 2004-06-29 2006-03-02 Matthew Piazza Viscous materials and method for producing
US7282194B2 (en) * 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
CN101171034B (en) 2005-03-03 2014-06-18 免疫医疗公司 Humanized L243 antibodies
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US20090226367A1 (en) * 2005-03-11 2009-09-10 Euro-Celtique S.A. Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
EP2949668B1 (en) 2005-05-18 2019-08-14 Ablynx N.V. Improved nanobodies tm against tumor necrosis factor-alpha
RU2433139C2 (en) 2005-05-20 2011-11-10 Аблинкс Н.В. Nanobodiec tm for treatment of aggregation-mediated diseases
EP2674440B1 (en) 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US8124598B2 (en) * 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
PT2118123E (en) 2007-01-31 2016-02-10 Harvard College Stabilized p53 peptides and uses thereof
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
US8491890B2 (en) 2008-07-09 2013-07-23 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting diseases of the central nervous system
AU2010254551B2 (en) * 2009-05-27 2016-10-20 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
EP2523680A4 (en) * 2010-01-11 2013-06-19 Ct Molecular Med & Immunology Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
NO2575876T3 (en) 2010-05-26 2018-05-05
PT2603600T (en) 2010-08-13 2019-02-27 Aileron Therapeutics Inc Peptidomimetic macrocycles
CA2843274A1 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
WO2013022968A1 (en) 2011-08-09 2013-02-14 Athera Biotechnologies Ab Antibodies binding to phosphorylcholine (pc) and/or pc conjugates
DK2742068T3 (en) 2011-08-09 2019-06-11 Athera Biotechnologies Ab NEW ANTIBODIES AGAINST PHOSPHORYLCHOLINE
CA2852468A1 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
EP2788020A4 (en) 2011-12-05 2015-04-29 Immunomedics Inc Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
RU2017145921A (en) 2012-02-15 2019-02-21 Эйлерон Терапьютикс, Инк. PEPTIDOMIMETIC MACROCYCLES
BR112015009470A2 (en) 2012-11-01 2019-12-17 Aileron Therapeutics Inc disubstituted amino acids and their methods of preparation and use
CN107753954A (en) 2012-12-13 2018-03-06 免疫医疗公司 The dosage of the antibody that effect is improved and toxicity reduces and SN 38 immunoconjugates
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP2988130A1 (en) * 2014-08-20 2016-02-24 Eppendorf Ag Method for coating a solid support
SG11201702223UA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
WO2016116907A1 (en) 2015-01-23 2016-07-28 Helix Biopharma Corporation Antibody-urease conjugates for therapeutic purposes
BR112017019738A2 (en) 2015-03-20 2018-05-29 Aileron Therapeutics Inc peptidomimetic macrocycles and their uses
CN107428837A (en) 2015-04-22 2017-12-01 免疫医疗公司 Circulate separation, detection, diagnosis and/or the identification of the positive cancer cells of TROP 2
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
CN108601841A (en) 2016-02-10 2018-09-28 免疫医疗公司 The combination of ABCG2 inhibitor and SACITUZUMAB GOVITECAN (IMMU-132) overcome the resistance to SN-38 in the cancer for expressing TROP-2
WO2017189279A1 (en) 2016-04-27 2017-11-02 Immunomedics, Inc. Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
US11491114B2 (en) 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
CN110392570A (en) 2017-03-27 2019-10-29 免疫医疗公司 With husky trastuzumab lattice dimension for the triple negative breast cancer of health and RAD51 inhibitor for treating expression TROP-2
EP3606964A4 (en) 2017-04-03 2020-12-09 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034756A (en) * 1971-01-13 1977-07-12 Alza Corporation Osmotically driven fluid dispenser
US3995631A (en) * 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4320759A (en) * 1980-04-28 1982-03-23 Alza Corporation Dispenser with diffuser
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4925678A (en) * 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
JPS63264069A (en) * 1987-04-22 1988-10-31 出光興産株式会社 Cell adhesive material
GB8826116D0 (en) * 1988-11-08 1988-12-14 Danbiosyst Ltd Adhesive drug delivery composition
US5320824A (en) * 1989-10-12 1994-06-14 Mallinckrodt Medical, Inc. Radionuclide labelled particles useful for radiation synovectomy
DE69218403T2 (en) * 1991-01-07 1997-06-26 Syngenix Ltd PARTICLES SUITABLE FOR ENDOCYTOSE
CA2079450A1 (en) * 1991-02-14 1992-08-15 Rimona Margalit Interaction between bioadhesive liposomes and target sites
CA2084194C (en) * 1991-04-02 2003-05-20 Gregory John Russell-Jones Oral delivery systems for microparticles

Also Published As

Publication number Publication date
CA2151742C (en) 1999-05-25
DE69411154D1 (en) 1998-07-23
MX9401351A (en) 1994-08-31
AU6268894A (en) 1994-09-14
US5702727A (en) 1997-12-30
EP0684814A1 (en) 1995-12-06
WO1994018955A1 (en) 1994-09-01
ATE167396T1 (en) 1998-07-15
DE69411154T2 (en) 1998-10-22
US5620708A (en) 1997-04-15
JPH08507070A (en) 1996-07-30
EP0684814B1 (en) 1998-06-17

Similar Documents

Publication Publication Date Title
CA2151742A1 (en) Compositions for Oral Delivery of Active Agents
EP2016950A8 (en) Pharmaceutical composition comprising an exendin-4 peptide
GR3034416T3 (en) Polysaccharide derivative and drug carrier.
US5258499A (en) Liposome targeting using receptor specific ligands
CA2329768A1 (en) Pharmaceutical composition comprising factor viii and neutral liposomes
CA2004532A1 (en) Peptide derivatives
DE69428442T2 (en) Inhalation PREPARATIONS
CA2249744A1 (en) Oral peptide pharmaceutical products
CA2122717A1 (en) Hemoglobins as drug delivery agents
CA2041093A1 (en) A pharmacological composition containing polyelectrolyte complexes in microparticulate form and at least one active substance
AU629903B2 (en) Mitomycin c derivatized with a hapten
IL95118A0 (en) Polypeptide derivatives,their preparation and pharmaceutical compositions containing them
BG104245A (en) Plasma protein-containing pharmaceutical compositions
CA2042503A1 (en) Novel bifunctional linking compounds, conjugates and methods for their production
EP1077070A3 (en) Oral drug delivery compositions
WO1999024076A3 (en) Salicylate derivatized therapeutic and diagnostic agents
JPH11507034A (en) Antigen processing cell targeting complex
JP2009529547A (en) Active agent-loaded nanoparticles based on hydrophilic proteins
KR20080042045A (en) Lipid construct for delivery of interferon to a mammal
CA2101332A1 (en) Antibody polycation conjugates
EP0306912A3 (en) Immunogenic composites capable of selectively inducing antibody production and pharmaceutical compositions employing the same.
JPH03505576A (en) Improvements related to organic compounds
CA2242750A1 (en) Antibodies with reduced net positive charge
EP0341661A3 (en) Peptide-drug compositions containing alpha-aminoboronic acid derivatives
AU6760294A (en) Immunotherapeutic peptides derived from toxic shock syndrome toxin-1, antibodies thereto, their uses in pharmaceutical compositions and diagnosis

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed